

Pillar III validates this computational model using *in vitro* and *in vivo* biological models and exploits it for the development of novel therapeutics

- The ALS computational model will be validated both clinically through the prospective population-based European validation cohort, and biologically in the abovementioned biological ALS models using functional genomics.

- New therapeutic lead compounds will be sought after by the establishment of the development of valorisation strategy and a new SME partner to be selected at a later stage in the project